Newly Launched International Study Aims to Better Inform Treatment
Options for Lung Cancer in a Unique, Underserved Population
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Foundation Medicine, Inc. (NASDAQ: FMI) today announced that it has
partnered with the Addario Lung Cancer Medical Institute (ALCMI) and
Bonnie J. Addario Lung Cancer Foundation (ALCF) to launch a first of its
kind, multi-center, international prospective study, the Genomics of
Young Lung Cancer. This study aims to better inform treatment decisions
in young adults with lung cancer by leveraging FoundationOne®, the only
commercially available and validated comprehensive genomic profile, to
look beyond the genomic alterations commonly associated with lung cancer
and identify the novel and unique alterations that present in lung
cancers in young adults. This insight, in combination with the expertise
of leading academic institutions and peer-reviewed literature, will be
applied to determine more effective treatment options and tailor
therapies precisely for these distinct and underserved patients.
In 2014, 224,000 new cases of lung cancer are expected to be diagnosed;
3,700 of these are expected to occur in patients under the age of 45.
Eighty percent of new lung cancer diagnoses are made in former or
never-smokers, and three percent of cancer diagnoses made in patients
younger than 45 will be lung cancer1.
"Lung cancer presents in a unique manner in young adults, who often do
not exhibit the characteristic symptoms and signs of a typical patient
with lung cancer," said Steven Young, President and COO of ALCMI.
"Despite an environment of rapidly expanding treatment options available
for lung cancer, a lack of understanding of comprehensive testing for
the molecular drivers of the disease specifically in young adults
restricts the effective treatments available to patients at a tragically
early stage in their lives. Through this initial study, we hope to
address this gap in knowledge and access, and lay the groundwork to
routinely identify more effective treatment options for these patients."
The Genomics of Young Lung Cancer study is designed to fit the unique
needs of young adults, allowing patients to remotely enroll in the trial
online or through their mobile phones. Through the extensive network of
community cancer centers available through the ALCMI consortium,
patients are able to participate at a location that is convenient for
them with minimal travel.
Principal Investigator on the trial, Barbara Gitlitz, MD, Associate
Professor of Medicine, University of Southern California, Norris
Comprehensive Cancer Center, said, "Lung cancer is fundamentally
different in young adults and the current standard of care does not
account for this distinction. This trial has the potential to
significantly improve treatment options for young adults through a more
thorough understanding of the genomic drivers of lung cancer unique to
"It is important to approach this often overlooked patient population
with a vision that is unbiased by our current observations of lung
cancer," said Deborah Morosini, MD, Vice President of Clinical
Development, Foundation Medicine. "Some of our prior work highlights
that lung cancer in young adults is biologically distinct, so it is
important to take a comprehensive approach to identify previously
unconsidered and novel alterations that may be driving the disease in
this population, and can be targeted with currently available
treatments. We are excited to be collaborating with the ALCMI consortium
on this innovative trial that we anticipate will ultimately inform novel
treatment strategies that will be more effective and better suited to
the life stage of these young patients."
Additional information about the study can be found at https://www.openmednet.org/site/alcmi-goyl
or by contacting Steven Young at (203) 226-5765 or firstname.lastname@example.org.
Individuals living outside the U.S. may contact ALCMI at email@example.com
for information on how to participate.
FoundationOne, the company's first clinical product, is a fully
informative genomic profile for solid tumors used by oncologists to
identify the molecular alterations in a patient's tumor and match those
alterations with relevant targeted therapies and clinical trials. Using
next-generation sequencing in routine cancer specimens, FoundationOne
interrogates all genes somatically altered in human cancers that are
validated targets for therapy or unambiguous drivers of oncogenesis
based on current knowledge. It reveals all classes of genomic
alterations including base substitutions, insertions, deletions, copy
number alterations and select rearrangements. FoundationOne fits easily
into the clinical workflow of the ordering physician, and test results
are provided in an easy-to-interpret report supported by a comprehensive
review of published literature. FoundationOne is a laboratory-developed
test performed at Foundation Medicine'sCLIA-certified lab. Please visit www.FoundationOne.com
for more information.
About Foundation Medicine
Foundation Medicine (NASDAQ: FMI) is a molecular information company
dedicated to a transformation in cancer care in which treatment is
informed by a deep understanding of the genomic changes that contribute
to each patient's unique cancer. The company's clinical assays,
FoundationOne for solid tumors and FoundationOne Heme for hematologic
malignancies, sarcomas and pediatric cancers, provide a fully
informative genomic profile to identify the molecular alterations in a
patient's cancer and match them with relevant targeted therapies and
clinical trials. Foundation Medicine's molecular information platform
aims to improve day-to-day care for patients by serving the needs of
clinicians, academic researchers and drug developers to help advance the
science of molecular medicine in cancer. For more information, please
or follow Foundation Medicine on Twitter (@FoundationATCG).
Foundation Medicine® and FoundationOne®
are registered trademarks of Foundation Medicine, Inc.
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995,
including, but not limited to, statements regarding the ability of the
Genomics of Young Lung Cancer study to better inform targeted treatment
decisions of adolescents and young adults with lung cancer and the
ability of the study design to fit the needs of certain cancer patients.
All such forward-looking statements are based on management's current
expectations of future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially and
adversely from those set forth in or implied by such forward-looking
statements. These risks and uncertainties include the risks that the
Genomics of Young Lung Cancer study will not identify unique genomic
signatures of lung cancer in its patient population; and the risks
described under the caption "Risk Factors" in Foundation Medicine's
Annual Report on Form 10-K for the year ended December 31, 2013, which
is on file with the Securities and Exchange Commission, as well as other
risks detailed in Foundation Medicine's subsequent filings with the
Securities and Exchange Commission. All information in this press
release is as of the date of the release, and Foundation Medicine
undertakes no duty to update this information unless required by law.
1. American Cancer Society. Cancer Facts and Figures 2014.
Pure Communications, Inc.
Foundation Medicine, Inc.
Source: Foundation Medicine, Inc.
News Provided by Acquire Media